KREBSBIOPharmaceuticals
Krebs Biochemicals & Industries Limited — Cash Flow Statement
₹39.75
-6.96%
Krebs Biochemicals & Industries Limited Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -11.45 Cr | -4.96 Cr | -35.58 Cr | -40.74 Cr | — |
| Capital Expenditure | -3.56 Cr | -7.33 Cr | -10.87 Cr | -23.52 Cr | — |
| End Cash Position | 0.14 Cr | 0.14 Cr | 0.09 Cr | 0.10 Cr | — |
| Beginning Cash Position | 0.14 Cr | 0.09 Cr | 0.10 Cr | 0.71 Cr | — |
| Changes In Cash | 42000.00 | 0.05 Cr | -0.01 Cr | -0.61 Cr | — |
| Financing Cash Flow | 12.86 Cr | 5.50 Cr | 37.34 Cr | 39.51 Cr | — |
| Net Other Financing Charges | 1000.00 | — | — | 1000.00 | — |
| Interest Paid Cff | -5.91 Cr | -4.69 Cr | -2.97 Cr | -5.39 Cr | — |
| Net Issuance Payments Of Debt | 18.78 Cr | 10.19 Cr | 40.32 Cr | 32.38 Cr | — |
| Net Short Term Debt Issuance | 41.03 Cr | -0.06 Cr | — | — | — |
| Net Long Term Debt Issuance | -22.25 Cr | 10.25 Cr | 40.32 Cr | 32.38 Cr | — |
| Investing Cash Flow | -4.97 Cr | -7.82 Cr | -12.64 Cr | -22.90 Cr | — |
| Net Other Investing Changes | -1.57 Cr | -0.49 Cr | -1.77 Cr | 0.62 Cr | — |
| Net PPE Purchase And Sale | -3.40 Cr | -7.33 Cr | -10.87 Cr | -23.52 Cr | — |
| Sale Of PPE | 0.16 Cr | 0.00 | — | — | — |
| Purchase Of PPE | -3.56 Cr | -7.33 Cr | — | — | — |
| Operating Cash Flow | -7.89 Cr | 2.36 Cr | -24.71 Cr | -17.22 Cr | — |
| Interest Paid Cfo | -0.02 Cr | 0.00 | — | — | — |
| Change In Working Capital | 6.64 Cr | 10.21 Cr | -9.84 Cr | 15.90 Cr | — |
| Change In Other Current Liabilities | 1.75 Cr | 9.30 Cr | -6.43 Cr | 13.07 Cr | — |
| Change In Other Current Assets | 0.36 Cr | -3.35 Cr | 5.15 Cr | -4.43 Cr | — |
| Change In Payable | -0.82 Cr | 3.69 Cr | -22.63 Cr | 17.13 Cr | — |
| Change In Inventory | 3.76 Cr | 2.15 Cr | 13.62 Cr | -8.96 Cr | — |
| Change In Receivables | 1.85 Cr | -1.38 Cr | 0.35 Cr | -0.58 Cr | — |
| Other Non Cash Items | 5.91 Cr | 4.69 Cr | 2.97 Cr | 5.39 Cr | — |
| Provisionand Write Offof Assets | -0.07 Cr | 0.43 Cr | 0.29 Cr | -0.28 Cr | — |
| Depreciation And Amortization | 6.69 Cr | 6.77 Cr | 6.56 Cr | 6.30 Cr | — |
| Depreciation | 6.69 Cr | 6.77 Cr | 6.37 Cr | 5.66 Cr | — |
| Gain Loss On Sale Of PPE | -0.12 Cr | 0.00 | — | — | — |
| Net Income From Continuing Operations | -26.92 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Net Common Stock Issuance | — | 0.00 | 0.00 | 12.51 Cr | 10.45 Cr |
| Other Cash Adjustment Outside Changein Cash | — | 2000.00 | 1000.00 | — | — |
| Amortization Cash Flow | — | 0.18 Cr | 0.18 Cr | 0.64 Cr | 0.26 Cr |
| Net Intangibles Purchase And Sale | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Krebs Biochemicals & Industries Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.